· Balaban, YH., Aka C, Koca-Caliskan U. Liver immunology and herbal treatment. World J Hepatol. 2017 Jun 18;9(17):757-770. doi: 10.4254/wjh.v9.i17.757.

· Balaban YH, Simşek H, Tatar G., Gastric cancer prevention from the point of Helicobacter. Turk J Gastroenterol, 25, 463-7 (2014). DOI: 10.5152/tjg.2014.8112

· Simsek, H., Pinar, A., Altinbas, A., Alp, A., Balaban, YH., Buyukasik, Y., Ozcebe, O., Hascelik, G., Gedikoglu, G., Tatar, G., “Alpha-1 antitrypsin deficiency in patients with chronic hepatitis,” Turk J Gastroenterol, 23, 569-73 (2012).

· Ergunay, E., Balaban, Y., Cosgun, E., Alp, A., Simsek, H., Sener, B., Tatar, G., Hascelik, G., “Epidemiologic trends in HBV infections at a reference centre in Turkey: an 11-year retrospective analysis,” Ann Hepatol, 11, 672-8 (2012).

· Tug, E., Balaban, YH., Kaplan Sahin, E., “Mapping of microsatellite instability in endoscopic normal colon,” Genet Test Mol Biomarkers, 16, 388-395 (2012). DOI: 10.1089/gtmb.2011.0219

· Dinis-Ribeiro, M., Areia, M., de Vries, AC., Marcos-Pinto, R., Monteiro-Soares, M., O'Connor, A., Pereira, C., Pimentel-Nunes, P., Correia, R., Ensari, A., Dumonceau, JM., Machado, JC., Macedo, G., Malfertheiner, P., Matysiak-Budnik, T., Megraud, F., Miki, K., O'Morain, C., Peek, RM., Ponchon, T., Ristimaki, A., Rembacken, B., Carneiro, F., Kuipers, EJ.; MAPS Participants., “Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED),” Endoscop, 44, 74-94 (2012).

· Simsek, H., Pinar, A., Altinbas, A., Alp, A., Balaban, YH., Buyukasik, Y., Ozcebe, O., Hascelik, G., Geikoglu, G., Tatar, G., “Cut off level to etect heterozygous alpha 1 antitrysin deficiency in Turkish population,” J Clin Lab Anal, 25:296-9 (2011).

· Balaban, YH., Korkusuz, P., Simsek, H., Gokcan, H., Gedikoglu, G., Pinar, A., Hascelik, G., Asan, E., Hamaloglu, E. and Tatar, G., “Dipeptidyl Peptidase IV (DDP IV) in NASH Patients,” Ann Hepatol, 6, 242-50 (2007).

· Simsek, H., Balaban, YH., Sumer, H. Yilmaz, E. and Tatar, G., “HFE Mutations Analysis of Turkish Patients with Nonalcoholic Steatohepatitis,” Dig Dis Sci, 51, 1723-4 (2006).

· Balaban, YH., Sumer, H., Simsek. H., Us, D. and Tatar, G., “Metabolic Syndrome, Non-Alcoholic Steatohepatitis (NASH), and Hepatocyte Growth Factor (HGF),” Ann Hepatol, 5, 109-14 (2006).

· van Zonneveld, M., Zondervan, PE., Cakaloglu, Y., Simon, C., Akarca, US., So, TM., Flink, HJ., de Man, RA., Schalm, SW., Janssen, HL.; HBV 99-01 Study Group., “Peg-interferon improves liver histology in patients with HBeAg-positive chronic hepatitis B: no additional benefit of combination with lamivudine,” Liver Int, 26(4), 399-405 (2006).

· Simsek, H., Balaban, YH., Yilmaz, E., Sumer, H., Buyukasik, Y., Cengiz, C., Ozcebe, O., Hascelik, G. and Tatar, G., “Mutations of the HFE Gene Among Turkish Hereditary Hemochromatosis Patients,” Ann Hematol, 84, 646-9 (2005).

· Simsek, H., Balaban, YH., Gunes, DD., Hascelik, G., Ozarlan, E. and Tatar, G., “Alarming Clarithromycin Resistance of Helicobacter Pylori in Turkish Population,” Helicobacter, 10, 360-1 (2005).

· The Turkish FMF Study Group, “Familial Mediterranean Fever (FMF) in Turkey: The Results of a Nationwide Multicenter Study,” Medicine, 84, 1-11 (2005).

· Elsuer, R., Tatar, G., Simsek, H., Balaban, YH. and Aydin, M. Sokmensuer, C., “Celiac Disease in the Turkish Population,” Dig Dis Sci, 50, 136-42 (2005).

· Janssen, HLA., van Zonneveld, M., Senturk, H., Zeuzem, S, Akarca, US., Cakaloglu, Y., Simon, C., So, TMK., Gerken, G., de Man, RA., Niesters, HGM., Zondervan, P., Hansen, B., Schalm, SW., for the HBV 99-01 Study Group., “Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial,” Lancet, 365, 123–29 (2005).

· Tatar, G., Elsurer, R., Simsek, H., Balaban, YH., Hascelik, G., Ozcebe, Oİ., Buyukasik, Y. and Sokmensuer, C., “The Screening of Tissue Transglutaminase Antibody in Healthy Blood Donors for Celiac Disease Screening in the Turkish Population” Dig Dis Sci, 49, 1479-84 (2004).

· Simsek, H., Sumer, H., Yilmaz, E., Balaban, YH., Ozcebe, O., Hascelik, G., Buyukasik, Y. and Tatar, G., “Frequency of HFE Mutations Among Turkish Blood Donors According to Transferrin Saturation,” J Clin Gastroenterol, 38, 671-5 (2004).

Karaciğer yağlanması, Metabolik ve viral karaciğer hastalıkları, Çölyak hastalığı (Gluten duyarlılığı), İnflamatuvar barsak hastalıkları

: (312) 305 17 13

: ybalaban@hacettepe.edu.tr